Robert W. Fairbairn, Director at BlackRock Capital Allocation Trust (BCAT), sold 91,282 shares at $19.72 ($1.8M) on 2021-11-22, disclosed to the SEC on 2021-11-24.
Open-market sale of $1.8M BCAT by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.69 | 38,141 | $751K | 41.8% |
| 2 | $19.69 | 38,141 | $751K | 41.8% |
| 3 | $19.72 | 3,500 | $69K | 3.8% |
| 4 | $19.73 | 7,100 | $140K | 7.8% |
| 5 | $19.74 | 1,660 | $33K | 1.8% |
| 6 | $19.74 | 100 |
| $2K |
| 0.1% |
| 7 | $19.75 | 60 | $1K | 0.1% |
| 8 | $19.75 | 200 | $4K | 0.2% |
| 9 | $19.76 | 40 | $790 | 0.0% |
| 10 | $19.76 | 840 | $17K | 0.9% |
| 11 | $19.77 | 101 | $2K | 0.1% |
| 12 | $19.78 | 1,399 | $28K | 1.5% |
| Total | $19.70 avg | 91,282 | $1.8M | 100% |
| Filing → |
| BSTZ | SELL | 2025-12-22 | $418K | — | Filing → |
| BTX | SELL | 2025-12-22 | $286K | — | Filing → |
| ECAT | BUY | 2022-05-13 | $1.2M | — | Filing → |